One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan
Ryo Mukai,Keiko Kataoka,Koji Tanaka,Yasunori Miyara,Ichiro Maruko,Makiko Nakayama,Yuto Watanabe,Akiko Yamamoto,Yu Wakatsuki,Hajime Onoe,Sorako Wakugawa,Nobuhiro Terao,Taiji Hasegawa,Moeko Kawai,Ruka Maruko,Kanako Itagaki,Jyunichiro Honjo,Annabelle A. Okada,Ryusaburo Mori,Hideki Koizumi,Tomohiro Iida,Tetsuju Sekiryu
DOI: https://doi.org/10.1038/s41598-024-62559-1
IF: 4.6
2024-05-24
Scientific Reports
Abstract:This multicentre retrospective study evaluated the 1-year outcomes and safety profile of faricimab in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). Fifty-five patients (57 eyes) underwent loading therapy comprising three monthly faricimab injections. If dryness was achieved by the third month, subsequent treat-and-extend (TAE) follow-up continued at a minimum 8-week interval thereafter. If wet macula persisted at the third month, a fourth dose was administered, followed by the TAE regimen. After 1 year, improvements in visual acuity (0.44 ± 0.46 [baseline] to 0.34 ± 0.48; p < 0.01) and central foveal thickness (326 ± 149 [baseline] to 195 ± 82 μm; p < 0.0001) were significant. Dry macula, characterised by the absence of intraretinal or subretinal fluid, was achieved in 65% of cases. Treatment intervals varied, ranging from 8 to 16 weeks, with 44% of eyes extending to a 16-week interval, followed by 33% at 8 weeks, 16% at 12 weeks, 5% at 14 weeks, and 2% at 10 weeks. Notably, 50% of the polypoidal choroidal vasculopathy patients exhibited complete regression of polypoidal lesions between 12 and 15 months. Faricimab treatment in nAMD patients induced significant improvements in central vision and retinal morphology. Two cases of retinal pigment epithelial tears and one case of iritis were reported as ocular complications.
multidisciplinary sciences